Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of -14.36% and Operating profit at -35.70% over the last 5 years
2
With a fall in Net Sales of -25.9%, the company declared Very Negative results in Mar 25
3
With ROE of 6.88%, it has a expensive valuation with a 3.05 Price to Book Value
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 8,132 Million (Mid Cap)
44.00
NA
0.00%
0.13
6.88%
3.05
Revenue and Profits:
Net Sales:
388 Million
(Quarterly Results - Jun 2025)
Net Profit:
14 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.78%
0%
-1.78%
6 Months
-1.17%
0%
-1.17%
1 Year
-13.14%
0%
-13.14%
2 Years
-38.28%
0%
-38.28%
3 Years
-37.47%
0%
-37.47%
4 Years
-30.72%
0%
-30.72%
5 Years
0%
0%
0.0%
Shenzhen YHLO Biotech Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-14.36%
EBIT Growth (5y)
-35.70%
EBIT to Interest (avg)
50.60
Debt to EBITDA (avg)
0.13
Net Debt to Equity (avg)
0.09
Sales to Capital Employed (avg)
0.66
Tax Ratio
11.06%
Dividend Payout Ratio
39.64%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
24.88%
ROE (avg)
18.68%
Valuation key factors
Factor
Value
P/E Ratio
44
Industry P/E
Price to Book Value
3.05
EV to EBIT
40.24
EV to EBITDA
17.40
EV to Capital Employed
2.81
EV to Sales
4.59
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
6.99%
ROE (Latest)
6.88%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
388.20
523.90
-25.90%
Operating Profit (PBDIT) excl Other Income
88.70
171.30
-48.22%
Interest
5.00
1.50
233.33%
Exceptional Items
2.20
-3.00
173.33%
Consolidate Net Profit
13.50
99.50
-86.43%
Operating Profit Margin (Excl OI)
47.70%
212.80%
-16.51%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -25.90% vs 26.76% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -86.43% vs 117.72% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,996.10
2,039.70
-2.14%
Operating Profit (PBDIT) excl Other Income
588.90
421.70
39.65%
Interest
15.40
7.50
105.33%
Exceptional Items
-26.20
57.40
-145.64%
Consolidate Net Profit
272.20
279.20
-2.51%
Operating Profit Margin (Excl OI)
166.80%
103.70%
6.31%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -2.14% vs -48.35% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -2.51% vs -72.66% in Dec 2023
About Shenzhen YHLO Biotech Co., Ltd. 
Shenzhen YHLO Biotech Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






